#ASCO17: Epizyme will hunt a quick OK for tazemetostat, despite disappointing analysts with new data
As the dust began to settle from the ASCO abstract drop last night, several analysts weighed in noting their cautious lack of optimism for Epizyme’s latest look at the data for tazemetostat, its EZH2 inhibitor now in Phase II for epithelioid sarcoma.
RBC’s Matthew Eckler noted the latest data were “below our expectations.”
For Geoffrey Porges at Leerink: “These results squeaked over the trial’s hurdle for proceeding to cohort expansion and the 13% ORR is below our mental threshold of a 20-30% response rate.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.